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INTRODUCTION
Multiple chemical sensitivity (MCS) is a clinical syndrome 
representing multi-organ and psychological symptoms caused 
by chronic exposure to various chemicals in low concentra-
tions.1,2 Idiopathic environmental intolerance (IEI) is another 
term for MCS as defined by the World Health Organization in 
1996.3 Although many patients suffer from MCS/IEI worldwide, 
many clinicians do not accept MCS/IEI as a well clarified dis-
ease condition because clinical manifestations of MCS/IEI are 
different from the direct toxicities of exposed chemicals.4
In the development of MCS/IEI, initial exposure to high con-
centration of culprit chemical is important but not crucial, and 
not all initial symptoms of MCS/IEI are related to high concen-
tration chemical exposure.5,6 Some possible mechanisms have 
been suggested for MCS/IEI development and propagation. 
Toxicant induced loss of tolerance theory explains that many 
different kinds of chemicals can be responsible for exacerba-
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tion of symptoms even if initial chemical exposures cause loss 
of tolerance.7 Psychiatric mechanisms may be involved in some 
patients who have complaints of somatoform symptoms like 
chronic fatigue syndrome and fibromyalgia.8 Recent research 
has suggested olfactory-limbic mechanisms such as hypersen-
sitivity of olfactory epithelium caused by chemical exposure in-
fluences on hormonal and emotional control of the hypothala-
mus.9
Although there are no international diagnostic criteria for 
MCS/IEI, repetitive symptoms after re-challenge, diminished 
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symptoms after de-challenge of chemical exposure and simul-
taneous multi-organ symptoms are frequently used for diagno-
sis of MCS/IEI.10 Therefore, Miller and Prihoda developed the 
environment exposure sensitivity inventory (EESI) and its short-
ened form quick EESI (QEESI©) to evaluate chemical exposure 
in daily life and sensitivity to those chemicals.11,12 The QEESI© is 
well validated and has been used in many countries to evaluate 
the possibility of MCS/IEI.13,14 Recently, the Korean version of 
the QEESI© was validated for use in predicting the possibility of 
MCS/IEI in Korean people.15 Although most people are exposed 
to low concentration of various chemicals in their daily lives, 
population-based studies on the prevalence and/or possible 
influencing factors of MCS/IEI are still lacking in Korea.
In this study, we evaluated the prevalence of MCS/IEI in the 
Korean population using the Korean version of the QEESI© to 
screen for the highly sensitive people and suggested the proba-
ble risk factors of development of MCS/IEI in Korea.
 
MATERIALS AND METHODS
Study participants
Participants were recruited from July first to August 31st, 2012 
at Severance Hospital. The Institutional Review Board of Yonsei 
University Health System approved this study (IRB no. 4-2012-
0328) and informed consent was obtained from all participants. 
A total 446 participants underwent systematic questionnaire 
interview. The questionnaire contained questions on sociode-
mographic variables (including age, sex, and smoking status), 
occupational and environmental factors and existence of aller-
gic disease.
Occupational and environmental factors included environ-
mental tobacco smoke exposure, experience of dwelling in a 
new house, household chemical use and occupational exposure 
to chemicals. Questions from the International Study of Asthma 
and Allergies in Childhood (ISAAC) questionnaire were adopt-
ed to assess asthma, allergic rhinitis and atopic dermatitis.16 Par-
ticipants were defined as allergic participants if they answered 
at least one of three questions (asthma, allergic rhinitis, and atop-
ic dermatitis questions from ISAAC) positively. Participants were 
also administered the Korean version of the QEESI©.15
Among all participants, 67 participants were excluded due to 
missing information in the questionnaire (n=55) and the QEE-
SI© (n=12). Finally, the data of 379 participants were analyzed.
Assessment of MCS/IEI
The QEESI© is a validated, self-administered instrument for 
evaluating multiple chemical intolerance. It consists of four 
subscales: symptom severity, chemical intolerance, other intol-
erance, and life impact. Total score for each scale is 100, and 
each scale can be divided into low, medium, and high. The cut-
off points are 20 and 40 for symptom severity and chemical in-
tolerance, 12 and 25 for other intolerance, and 12 and 24 for life 
impact. According to the QEESI© interpretation results, partici-
pants were divided into four groups: not suggestive group (symp-
tom severity score <40 and chemical intolerance score <40; 
symptom severity score ≥40, chemical score <40, and mask-
ing score <4), problematic group (symptom severity score <40 
and chemical intolerance score ≥40), somewhat suggestive 
group (symptom severity score ≥40, chemical intolerance 
score <40, and masking score ≥4), and very suggestive group 
(symptom severity score ≥40 and chemical intolerance score 
≥40).11 In the analysis, the three groups other than the very 
suggestive (VS) group were merged into one group (less sug-
gestive group, LS group).
Statistical methods
In order to compare the characteristics of the LS group and VS 
group, Student’s t-tests and chi-square tests were conducted for 
continuous variables and categorized variables. Odds ratios 
(ORs) and 95% confidence intervals (95% CIs) were estimated 
by multivariate logistic regression analysis defining the sugges-
tive level of MCS/IEI as the dependent variable. Participants 
were then stratified into allergic group and non-allergic group, 
and ORs and 95% CIs were calculated for each group.
All statistical tests were 2-tailed, and P values of less than 0.05 
were regarded as statistically significant. All statistical analyses 
were conducted with the SAS software package version 9.2 (SAS 
Institute, Cary, NC, USA).
RESULTS
Demographic findings of study participants
The general characteristics of study participants are shown in 
Table 1. Sixty two participants were classified into the VS group 
and 317 into the LS group. Among them, 228 participants (60.2%) 
had at least one allergic disease. The mean age of total partici-
pants and in each group was 39.8±10.1 (total), 38.9±9.5 (VS 
group), and 38.1±11.5 (LS group). Females showed a higher 
prevalence of MCS/IEI than males (P=0.03). The proportion of 
non-smokers, asthma patients, allergic rhinitis patients, and 
atopic dermatitis patients were higher in the VS group. Howev-
er, only the proportion of atopic dermatitis patients showed a 
significant difference (P=0.02). In the stratified analysis, there 
were no significant differences in the proportion of sex, smok-
ers in both the allergic and non-allergic group and in the pro-
portion of asthma patients, allergic rhinitis patients, and atopic 
dermatitis patients in the allergic group.
Environmental chemical exposures
Many of participants had been exposed to environmental to-
bacco smoke, lived in a new house, and had been exposed to 
chemicals at work. Participants who sometimes used household 
chemicals were included in the VS group more likely. However, 
only the experience of dwelling in a new house showed signifi-
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cant difference (Table 2). In the stratified analysis, there was no 
significant difference to exposures between LS and VS group.
Prevalence of MCS/IEI and related factors
The proportion of participants classified into the VS group was 
Table 1. General characteristics of study participants
Allergic Non-allergic Total
LS VS P value LS VS P value LS VS P value
Age (year) 0.08 0.76* 0.09
Less than 30 64 (90.1) 7 (9.9) 26 (92.9) 2 (7.1) 90 (90.9) 9 (9.1)
30-39 51 (73.9) 18 (26.1) 34 (85.0) 6 (15.0) 85 (78.0) 24 (22.0)
40-49 36 (76.6) 11 (23.4) 51 (87.9) 7 (12.1) 87 (82.9) 18 (17.1)
50 or more 32 (78.1) 9 (22.0) 23 (92.0) 2 (8.0) 55 (83.3) 11 (16.7)
Sex   0.33   0.09   0.03
Male 78 (83.9) 15 (16.1) 81 (93.1) 6 (6.9) 159 (88.3) 21 (11.7)
Female 105 (77.8) 30 (22.2) 53 (82.8) 11 (17.2) 158 (79.4) 41 (20.6)
Smoking   0.68   0.96*   0.80
Yes 18 (75.0) 6 (25.0) 30 (93.8) 2 (6.3) 48 (85.7) 8 (14.3)
No 165 (80.9) 39 (19.1) 104 (87.4) 15 (12.6) 269 (83.3) 54 (16.7)
Asthma   1.00   0.62
Yes 55 (80.9) 13 (19.1) 55 (80.9) 13 (19.1)
No 128 (80.0) 32 (20.0) 262 (84.2) 49 (15.8)
Allergic rhinitis   0.93   0.07
Yes 151 (79.9) 38 (20.1) 151 (79.9) 38 (20.1)
No 32 (82.1) 7 (18.0) 166 (87.4) 24 (12.6)
Atopic dermatitis   0.20   0.02
Yes 68 (75.6) 22 (24.4) 68 (75.6) 22 (24.4)
No 115 (83.3) 23 (16.7) 249 (86.2) 40 (13.8)
Data are presented as number (percent).
*P value by Fisher’s exact test.
VS, very suggestive; LS, less suggestive.
Table 2. Environmental chemical exposures of study participants
Allergic Non-allergic Total
LS VS P value LS VS P value LS VS P value
ETS exposure 0.33 0.82 0.34
Yes 53 (75.7) 17 (24.3) 47 (87.0) 7 (13.0) 100 (80.7) 24 (19.4)
No 130 (82.3) 28 (17.7) 87 (89.7) 10 (10.3) 217 (85.1) 38 (14.9)
Experience of dwellingin a new house  0.16   0.07   0.01
Yes 120 (77.4) 35 (22.6) 75 (84.3) 14 (15.7) 195 (79.9) 49 (20.1)
No 63 (86.3) 10 (13.7) 59 (95.2) 3 (4.8) 122 (90.4) 13 (9.6)
Occupational chemical exposure  1.00   0.77   0.95
Yes 52 (80.0) 13 (20.0) 46 (86.8) 7 (13.2) 98 (83.1) 20 (17.0)
No 131 (80.4) 32 (19.6) 88 (89.8) 10 (10.2) 219 (83.9) 42 (16.1)
Household Chemical Use   0.36   0.66   0.78
No or seldom 51 (81.0) 12 (19.1) 36 (90.0) 4 (10.0) 87 (84.5) 16 (15.3)
Sometimes 58 (75.3) 19 (24.7) 50 (90.9) 5 (9.1) 108 (81.8) 24 (18.2)
Often 74 (84.1) 14 (15.9) 48 (85.7) 8 (14.3) 122 (84.7) 22 (15.5)
Household chemical use: seldom≤once a month; once a month<sometimes≤once a week; often>once a week.
Data are presented as number (percent).
VS, very suggestive; LS, less suggestive; ETS, environmental tobacco smoke.
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16.4% in this study, and was higher in allergic patients than in 
non-allergic participants (19.7% and 11.3%, Table 3). The differ-
ence in suggestive degree between allergic and non-allergic 
participants was not statistically significant in the four-group 
comparison (P=0.07). However, the difference became signifi-
cant when the not suggestive, the problematic, and the some-
what suggestive group were merged into less suggestive group 
(P=0.04). The mean scores of the QEESI© subscales: symptom 
severity, chemical intolerance, other intolerance, and life impact 
showed significant differences between the allergic and non-al-
lergic group, however, none of them exceeded the high cut-off 
level (Table 4). The proportion of participants classified as ‘high’ 
was also higher in the allergic group in all subscales (symptom 
severity: 26.3% in allergic, 14.6% in non-allergic, P<0.01, chemi-
cal intolerance: 41.2% in allergic, 31.1% in non-allergic, P=0.06, 
other intolerance: 33.5% in allergic, 18.1% in non-allergic, P<0.01, 
and life impact: 34.2% in allergic, 20.7% in non-allergic, P<0.01).
In the multivariate logistic regression analysis, participants in 
their fourth and fifth decade and females were more likely to be 
included in the VS group. The ORs for these groups were 2.94 
(95% CI 1.25-6.95), 2.51 (1.02-6.21), and 2.16 (1.11-4.18), respec-
tively. Participants with experience of dwelling in a new house 
and atopic dermatitis showed ORs of 2.05 (1.04-4.03) and 1.95 
(1.04-3.69), respectively. In the allergic group, female sex, expe-
rience of dwelling in a new house, and atopic dermatitis became 
non-significant when stratified; only age of 30-39 remained sig-
nificant (3.14, 1.16-8.45) (Table 5).
DISCUSSION
MCS/IEI is an emerging medical issue worldwide. However, 
diagnostic and therapeutic measures for MCS/IEI are still con-
troversial.17 Moreover, its exact prevalence is unclear. To the au-
thors’ knowledge, this is the first study to report the prevalence 
and related risk factors of MCS/IEI targeting allergic and non-
allergic Korean adults using the QEESI©. Participants were re-
cruited from Severance Hospital, and regarded as having MCS/
Table 3. Distribution of participants by suggestive degree group
Allergic Non-allergic Total P value
Less suggestive 220 (80.3) 134 (88.7) 317 (83.6) 0.04*
Not suggestive 122 (53.5) 99 (65.6) 221 (58.3) 0.07†
Problematic 49 (21.5) 30 (19.9) 79 (20.8)
Somewhat suggestive 12 (5.3) 5 (3.3) 17 (4.5)
Very suggestive 45 (19.7) 17 (11.3) 62 (16.4)
Data are presented as number (percent).
*Less suggestive versus very suggestive; †Four-group comparison.
Table 4. Mean scores of the QEESI© subscales
Allergic Non-allergic Total P value
Symptom severity 29.9 (±19.4) 20.4 (±18.2) 26.1 (±19.5) <0.01
Chemical intolerance 35.0 (±23.3) 28.1 (±21.9) 32.3 (±23.0) <0.01
Other intolerance 21.4 (±18.0) 12.5 (±13.7) 17.9 (±17.0) <0.01
Life impact 20.5 (±22.2) 11.0 (±14.4) 16.7 (±20.0) <0.01
Masking index 5.1 (±1.5) 5.0 (±1.4) 5.1 (±1.5) 0.25
Data are presented as mean (±SD).
Table 5. Odd ratios for very suggestive of MCS/IEI in relation to risk factors
Allergic Non-allergic Total
OR 95% CI OR 95% CI OR 95% CI
Age (Reference: <30 years) 1.00 Reference 1.00 Reference 1.00 Reference
30-39 3.14 1.16-8.45 2.21 0.38-12.93 2.94 1.25-6.95
40-49 2.83 0.97-8.27 1.69 0.31-9.30 2.51 1.02-6.21
50 or more 2.61 0.83-8.23 1.32 0.16-11.22 2.25 0.83-6.14
Female sex (Reference: male) 2.00 0.90-4.44 2.55 0.77-8.39 2.16 1.11-4.18
Smoking 2.28 0.73-7.10 0.86 0.15-4.85 1.49 0.59-3.76
ETS exposure 1.35 0.66-2.78 1.27 0.43-3.79 1.32 0.74-2.38
Experience of dwelling in a new house 1.75 0.78-3.92 3.27 0.86-12.35 2.05 1.04-4.03
Occupational chemical exposure 1.01 0.46-2.21 1.16 0.37-3.60 1.09 0.58-2.03
Household chemical use (Reference: no or seldom) 1.00 Reference 1.00 Reference 1.00 Reference
Sometimes 1.38 0.58-3.28 0.67 0.15-2.99 1.15 0.55-2.39
Often 0.86 0.34-2.18 1.26 0.32-5.04 0.99 0.47-2.11
Asthma 0.86 0.40-1.86 0.93 0.44-1.96
Allergic rhinitis 1.48 0.54-4.02 1.54 0.81-2.91
Atopic dermatitis 1.85 0.89-3.81 1.95 1.04-3.69
Household chemical use: seldom≤once a month; once a month<sometimes≤once a week; often>once a week.
ETS, Environmental tobacco smoke.
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IEI when classified into the VS group. In Korea, studies report-
ing case or prevalence of MCS/IEI are scarce. There is a report 
of MCS/IEI in farmers exposed to pesticides and one study re-
ported the prevalence of MCS/IEI using the QEESI©.15,18 The es-
timated prevalence of MCS/IEI was 16.4% in the present study. 
There was a difference in prevalence according to existence of 
allergic disease; prevalence in allergic patients was 19.7% and 
11.3% in non-allergic participants. Age, female sex, experience 
of dwelling in a new house, and atopic dermatitis were found to 
be significantly related factors.
A number of other studies used the QEESI©. Prevalence was 
20.3% in a study conducted in clinics in the U.S. and 20.3% and 
21.7% in Korea if the same diagnostic criteria used in this study 
are applied.15,19 In studies using other diagnostic criteria, preva-
lence of 15.9%, 12.5%, and 11.2% in the U.S. were reported, and 
a prevalence of 9% was reported in Germany.20-23 In our study, 
the prevalence in total participants was 16.4%, and when par-
ticipants are divided by recruiting site, prevalence was 20.8% in 
allergy clinic patients and 12.8% in health examination center 
visitors. The prevalence in total participants was similar to the 
results from the U.S., even though different diagnostic criteria 
were used, and the prevalence in clinic patients was also simi-
lar to that of U.S. clinic patients. However, other studies have 
shown different prevalence. The study conducted in Germany 
showed relatively lower prevalence due to the application of 
stricter diagnostic criteria, and the other Korean study showed 
relatively higher prevalence, most likely due to the demograph-
ic differences of subjects in this study.
In previous studies exploring the initiating factors of MCS/IEI, 
frequently reported factors or agents were solvents, cleaners, 
indoor air contaminants, pesticides, and job-related chemical 
exposures.12,24,25 In this study, only the experience of dwelling in 
a new house was significantly related. Exposure to indoor air 
contaminants in a newly built home or school was also the most 
common onset factor in a Japanese study.25 This may be because 
people living in newly built houses are often exposed to various 
kinds of volatile organic compounds.26 However, the relation-
ship between MCS/IEI and job-related chemical exposure was 
not significant. One possible explanation is the non-differential 
misclassification of job-related chemical exposure which tends 
to bias the associations towards the null. Another possible ex-
planation is that because the analysis was conducted with cur-
rent job or job-related exposure, effects from former jobs or ex-
posures could not be assessed. The relationship between MCS/
IEI and pesticide use could not be assessed because most partic-
ipants lived in urban areas, and only one participant reported 
pesticide use.
MCS/IEI and allergic diseases are known to be related to each 
other,27 and associations have been reported in previous stud-
ies.19,25,28 In this study, the prevalence between the allergic and 
non-allergic groups was also different, and the average scores 
of the QEESI© subscales also showed differences, except for the 
masking index. One possible explanation is that the perception 
of chemical exposure of allergic patients was higher than that of 
non-allergic participants. In general, symptoms of allergic air-
way disease could be aggravated when patients are exposed to 
cold and dry air, air pollutants, and environmental chemicals. 
Volatile organic compounds and phthalates are well known 
chemical irritants in asthmatics.29,30 However, unlike other pre-
vious studies that reported asthma and rhinitis as comorbid di-
agnoses,31,32 only atopic dermatitis was significantly related to 
MCS/IEI in this study.
This study has several limitations. First, due to the cross-sec-
tional design, there could be recall bias regarding information 
on chemical exposures at work or home. Second, because in-
formation about participants in this study was only obtained 
via questionnaire, there could be some false positives or false 
negatives. In order to reduce this risk, validated questionnaires 
were used and people with acute disease or severe symptoms 
were not recruited. Third, this study had limited statistical pow-
er due to the small number of participants. Therefore, some dif-
ferences did not reach statistical significance in stratified analy-
sis. Lastly, this is an epidemiologic study; thereby has difficulty 
in explaining mechanisms of development of MCS/IEI. 
MCS/IEI patients can frequently present multi-organ and psy-
chological symptoms. Moreover, common somatic symptoms 
they complain include central nervous system symptoms (i.e., 
headache, fatigue, and cognitive deficit), musculoskeletal symp-
toms, gastrointestinal symptoms, and dermatologic symp-
toms.1,2,33 Although there are no universal diagnostic criteria or 
tests for MCS/IEI, patients could be referred to allergists for 
evaluation of culprit agents. Therefore, it is important to suspect 
MCS/IEI in a patient with MCS/IEI features described above 
rather than ignore patients’ complaints in an allergy clinic.
In conclusion, the estimated prevalence of MCS/IEI in present 
study was 16.4%, and was higher among allergic patients than 
non-allergic participants (19.5%, 11.3%, respectively). People 
with experience of dwelling in a new house and atopic derma-
titis are more at risk of being intolerant to chemicals. Further 
studies to provide the nationally representative prevalence data 
and clarify risk factors, mechanisms, and the relationship be-
tween allergic disease and MCS/IEI are required.
REFERENCES
1. Sparks PJ, Daniell W, Black DW, Kipen HM, Altman LC, Simon GE, 
Terr AI. Multiple chemical sensitivity syndrome: a clinical perspec-
tive. II. Evaluation, diagnostic testing, treatment, and social consid-
erations. J Occup Med 1994;36:731-7.
2. Graveling RA, Pilkington A, George JP, Butler MP, Tannahill SN. A 
review of multiple chemical sensitivity. Occup Environ Med 1999; 
56:73-85.
3. Conclusions and recommendations of a workshop on Multiple 
Chemical Sensitivities (MCS): February 21-23, 1996, Berlin, Ger-
many. Regul Toxicol Pharmacol 1996;24:S188-9.
Jeong et al. Volume 6, Number 5, September 2014
Allergy Asthma Immunol Res. 2014 September;6(5):409-414. http://dx.doi.org/10.4168/aair.2014.6.5.409414 http://e-aair.org
4. Gibson PR, Lindberg A. Physicians’ perceptions and practices re-
garding patient reports of multiple chemical sensitivity. ISRN Nurs 
2011;2011:838930. doi: 10.5402/2011.838930.
5. Watanabe M, Tonori H, Aizawa Y. Multiple chemical sensitivity and 
idiopathic environmental intolerance (part one). Environ Health 
Prev Med 2003;7:264-72.
6. Watanabe M, Tonori H, Aizawa Y. Multiple chemical sensitivity and 
idiopathic environmental intolerance (part two). Environ Health 
Prev Med 2003;7:273-82.
7. Sparks PJ, Daniell W, Black DW, Kipen HM, Altman LC, Simon GE, 
Terr AI. Multiple chemical sensitivity syndrome: a clinical perspec-
tive. I. Case definition, theories of pathogenesis, and research needs. 
J Occup Med 1994;36:718-30.
8. Pall ML. Common etiology of posttraumatic stress disorder, fibro-
myalgia, chronic fatigue syndrome and multiple chemical sensitiv-
ity via elevated nitric oxide/peroxynitrite. Med Hypotheses 2001; 
57:139-45.
9. Orriols R, Costa R, Cuberas G, Jacas C, Castell J, Sunyer J. Brain dys-
function in multiple chemical sensitivity. J Neurol Sci 2009;287:72-8.
10. Multiple chemical sensitivity: a 1999 consensus. Arch Environ Health 
1999;54:147-9.
11. Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity 
Inventory (EESI): a standardized approach for measuring chemi-
cal intolerances for research and clinical applications. Toxicol Ind 
Health 1999;15:370-85.
12. Miller CS, Prihoda TJ. A controlled comparison of symptoms and 
chemical intolerances reported by Gulf War veterans, implant re-
cipients and persons with multiple chemical sensitivity. Toxicol 
Ind Health 1999;15:386-97.
13. Nordin S, Andersson L. Evaluation of a Swedish version of the Quick 
Environmental Exposure and Sensitivity Inventory. Int Arch Occup 
Environ Health 2010;83:95-104.
14. Hojo S, Kumano H, Yoshino H, Kakuta K, Ishikawa S. Application 
of Quick Environment Exposure Sensitivity Inventory (QEESI) for 
Japanese population: study of reliability and validity of the ques-
tionnaire. Toxicol Ind Health 2003;19:41-9.
15. Jeon BH, Lee SH, Kim HA. A validation of the Korean version of 
QEESI(c) (The Quick Environmental Exposure and Sensitivity In-
ventory). Korean J Occup Environ Med 2012;24:96-114.
16. Asher MI, Keil U, Anderson HR, Beasley R, Crane J, Martinez F, 
Mitchell EA, Pearce N, Sibbald B, Stewart AW, Strachan D, Weiland 
SK, Williams HC. International Study of Asthma and Allergies in 
Childhood (ISAAC): rationale and methods. Eur Respir J 1995;8:483-
91.
17. Hetherington L, Battershill J. Review of evidence for a toxicological 
mechanism of idiopathic environmental intolerance. Hum Exp 
Toxicol 2013;32:3-17.
18. Lee HS, Hong SY, Hong ZR, Gil HO, Yang JO, Lee EY, Han MJ, Jang 
NW, Hong SY. Pesticide-initiated idiopathic environmental intoler-
ance in South Korean farmers. Inhal Toxicol 2007;19:577-85.
19. Katerndahl DA, Bell IR, Palmer RF, Miller CS. Chemical intolerance 
in primary care settings: prevalence, comorbidity, and outcomes. 
Ann Fam Med 2012;10:357-65.
20. Kreutzer R, Neutra RR, Lashuay N. Prevalence of people reporting 
sensitivities to chemicals in a population-based survey. Am J Epi-
demiol 1999;150:1-12.
21. Caress SM, Steinemann AC. Prevalence of multiple chemical sen-
sitivities: a population-based study in the southeastern United 
States. Am J Public Health 2004;94:746-7.
22. Caress SM, Steinemann AC. A national population study of the 
prevalence of multiple chemical sensitivity. Arch Environ Health 
2004;59:300-5.
23. Hausteiner C, Bornschein S, Hansen J, Zilker T, Förstl H. Self-re-
ported chemical sensitivity in Germany: a population-based sur-
vey. Int J Hyg Environ Health 2005;208:271-8.
24. Caress SM, Steinemann AC, Waddick C. Symptomatology and eti-
ology of multiple chemical sensitivities in the southeastern United 
States. Arch Environ Health 2002;57:429-36.
25. Hojo S, Ishikawa S, Kumano H, Miyata M, Sakabe K. Clinical char-
acteristics of physician-diagnosed patients with multiple chemical 
sensitivity in Japan. Int J Hyg Environ Health 2008;211:682-9.
26. Shin SH, Jo WK. Volatile organic compound concentrations, emis-
sion rates, and source apportionment in newly-built apartments at 
pre-occupancy stage. Chemosphere 2012;89:569-78.
27. Meggs WJ. Mechanisms of allergy and chemical sensitivity. Toxicol 
Ind Health 1999;15:331-8.
28. Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. Preva-
lence and nature of allergy and chemical sensitivity in a general 
population. Arch Environ Health 1996;51:275-82.
29. Wieslander G, Norbäck D, Björnsson E, Janson C, Boman G. Asth-
ma and the indoor environment: the significance of emission of 
formaldehyde and volatile organic compounds from newly paint-
ed indoor surfaces. Int Arch Occup Environ Health 1997;69:115-24.
30. Jaakkola JJ, Ieromnimon A, Jaakkola MS. Interior surface materials 
and asthma in adults: a population-based incident case-control 
study. Am J Epidemiol 2006;164:742-9.
31. Bell IR, Schwartz GE, Peterson JM, Amend D. Self-reported illness 
from chemical odors in young adults without clinical syndromes 
or occupational exposures. Arch Environ Health 1993;48:6-13.
32. Baldwin CM, Bell IR. Increased cardiopulmonary disease risk in a 
community-based sample with chemical odor intolerance: impli-
cations for women’s health and health-care utilization. Arch Envi-
ron Health 1998;53:347-53.
33. Lacour M, Zunder T, Schmidtke K, Vaith P, Scheidt C. Multiple 
chemical sensitivity syndrome (MCS)--suggestions for an exten-
sion of the U.S. MCS-case definition. Int J Hyg Environ Health 2005; 
208:141-51.
